The breast is yet to come: current and future utility of circulating tumour DNA in breast cancer.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
08
09
2020
accepted:
21
04
2021
revised:
02
04
2021
pubmed:
28
5
2021
medline:
18
12
2021
entrez:
27
5
2021
Statut:
ppublish
Résumé
Advances in genomic strategies and the development of targeted therapies have enabled precision medicine to revolutionise the field of oncology. Precision medicine uses patient-specific genetic and molecular information, traditionally obtained from tumour biopsy samples, to classify tumours and treat them accordingly. However, biopsy samples often fail to provide complete tumour profiling, and the technique is expensive and, of course, relatively invasive. Advances in genomic techniques have led to improvements in the isolation and detection of circulating tumour DNA (ctDNA), a component of a peripheral blood draw/liquid biopsy. Liquid biopsy offers a minimally invasive method to gather genetic information that is representative of a global snapshot of both primary and metastatic sites and can thereby provide invaluable information for potential targeted therapies and methods for tumour surveillance. However, a lack of prospective clinical trials showing direct patient benefit has limited the implementation of liquid biopsies in standard clinical applications. Here, we review the potential of ctDNA obtained by liquid biopsy to revolutionise personalised medicine and discuss current applications of ctDNA both at the benchtop and bedside.
Identifiants
pubmed: 34040179
doi: 10.1038/s41416-021-01422-w
pii: 10.1038/s41416-021-01422-w
pmc: PMC8438047
doi:
Substances chimiques
Biomarkers, Tumor
0
Circulating Tumor DNA
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
780-788Subventions
Organisme : NCI NIH HHS
ID : R01 CA194024
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA214494
Pays : United States
Informations de copyright
© 2021. The Author(s), under exclusive licence to Cancer Research UK.
Références
Meisel, J. L., Venur, V. A., Gnant, M. & Carey, L. Evolution of targeted therapy in breast cancer: where precision medicine began. Am. Soc. Clin. Oncol. Educ. Book 38, 78–86 (2018).
pubmed: 30231395
doi: 10.1200/EDBK_201037
Condorelli, R., Mosele, F., Verret, B., Bachelot, T., Bedard, P. L., Cortes, J. et al. Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann. Oncol. 30, 365–373 (2019).
pubmed: 30715161
doi: 10.1093/annonc/mdz036
Overman, M. J., Modak, J., Kopetz, S., Murthy, R., Yao, J. C., Hicks, M. E. et al. Use of research biopsies in clinical trials: are risks and benefits adequately discussed? J. Clin. Oncol. 31, 17–22 (2013).
pubmed: 23129736
doi: 10.1200/JCO.2012.43.1718
Poulet, G., Massias, J. & Taly, V. Liquid biopsy: general concepts. Acta Cytol. 63, 449–455 (2019).
pubmed: 31091522
doi: 10.1159/000499337
Chae, Y. K., Davis, A. A., Jain, S., Santa-Maria, C., Flaum, L., Beaubier, N. et al. Concordance of genomic alterations by next-generation sequencing in tumor tissue versus circulating tumor DNA in breast cancer. Mol. Cancer Ther. 16, 1412–1420 (2017).
pubmed: 28446639
doi: 10.1158/1535-7163.MCT-17-0061
Davis, A. A., Jacob, S., Gerratana, L., Shah, A. N., Wehbe, F., Katam, N. et al. Landscape of circulating tumour DNA in metastatic breast cancer. EBioMedicine 58, 102914 (2020).
pubmed: 32707446
pmcid: 7381501
doi: 10.1016/j.ebiom.2020.102914
Nishimura, F., Uno, N., Chiang, P. C., Kaku, N., Morinaga, Y., Hasegawa, H. et al. The effect of in vitro hemolysis on measurement of cell-free DNA. J. Appl. Lab. Med. 4, 235–240 (2019).
pubmed: 31639669
doi: 10.1373/jalm.2018.027953
Sorber, L., Zwaenepoel, K., De Winne, K., Van Casteren, K., Augustus, E., Jacobs, J. et al. A multicenter study to assess EGFR mutational status in plasma: focus on an optimized workflow for liquid biopsy in a clinical setting. Cancers 10, 290 (2018).
pmcid: 6162772
doi: 10.3390/cancers10090290
Toro, P. V., Erlanger, B., Beaver, J. A., Cochran, R. L., VanDenBerg, D. A., Yakim, E. et al. Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA. Clin. Biochem. 48, 993–998 (2015).
pubmed: 26234639
pmcid: 4600652
doi: 10.1016/j.clinbiochem.2015.07.097
Toro, P. V., Erlanger, B., Beaver, J. A., Cochran, R. L., VanDenBerg, D. A., Yakim, E. et al. Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA. Clin. Biochem. https://doi.org/10.1016/j.clinbiochem.2015.07.097 (2015).
Medford, A. J., Gillani, R. N. & Park, B. H. Detection of cancer DNA in early stage and metastatic breast cancer patients. Methods Mol. Biol. 1768, 209–227 (2018).
pubmed: 29717446
doi: 10.1007/978-1-4939-7778-9_13
Sorenson, G. D., Pribish, D. M., Valone, F. H., Memoli, V. A., Bzik, D. J. & Yao, S. L. Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol. Biomarkers Prev. 3, 67–71 (1994).
pubmed: 8118388
Hindson, C. M., Chevillet, J. R., Briggs, H. A., Gallichotte, E. N., Ruf, I. K., Hindson, B. J. et al. Absolute quantification by droplet digital PCR versus analog real-time PCR. Nat. Methods 10, 1003–1005 (2013).
pubmed: 23995387
pmcid: 4118677
doi: 10.1038/nmeth.2633
Miyazawa, H., Tanaka, T., Nagai, Y., Matsuoka, M., Huqun, Sutani, A. et al. Peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based detection test for gefitinib-refractory T790M epidermal growth factor receptor mutation. Cancer Sci. 99, 595–600 (2008).
pubmed: 18271876
doi: 10.1111/j.1349-7006.2007.00706.x
Wang, H., Jiang, J., Mostert, B., Sieuwerts, A., Martens, J. W., Sleijfer, S. et al. Allele-specific, non-extendable primer blocker PCR (AS-NEPB-PCR) for DNA mutation detection in cancer. J. Mol. Diagn. 15, 62–69 (2013).
pubmed: 23159590
doi: 10.1016/j.jmoldx.2012.08.007
Diehl, F., Li, M., He, Y., Kinzler, K. W., Vogelstein, B. & Dressman, D. BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions. Nat. Methods 3, 551–559 (2006).
pubmed: 16791214
doi: 10.1038/nmeth898
Taniguchi, K., Uchida, J., Nishino, K., Kumagai, T., Okuyama, T., Okami, J. et al. Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin. Cancer Res. 17, 7808–7815 (2011).
pubmed: 21976538
doi: 10.1158/1078-0432.CCR-11-1712
Hindson, B. J., Ness, K. D., Masquelier, D. A., Belgrader, P., Heredia, N. J., Makarewicz, A. J. et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal. Chem. 83, 8604–8610 (2011).
pubmed: 22035192
pmcid: 3216358
doi: 10.1021/ac202028g
O’Leary, B., Hrebien, S., Beaney, M., Fribbens, C., Garcia-Murillas, I., Jiang, J. et al. Comparison of BEAMing and Droplet Digital PCR for Circulating Tumor DNA Analysis. Clin Chem 65, 1405–1413 (2019).
pubmed: 31551314
doi: 10.1373/clinchem.2019.305805
Taylor, S. C., Laperriere, G. & Germain, H. Droplet digital PCR versus qPCR for gene expression analysis with low abundant targets: from variable nonsense to publication quality data. Sci. Rep. 7, 2409 (2017).
pubmed: 28546538
pmcid: 5445070
doi: 10.1038/s41598-017-02217-x
Chen, M. & Zhao, H. Next-generation sequencing in liquid biopsy: cancer screening and early detection. Hum. Genomics 13, 34 (2019).
pubmed: 31370908
pmcid: 6669976
doi: 10.1186/s40246-019-0220-8
El Achi, H., Khoury, J. D. & Loghavi, S. Liquid biopsy by next-generation sequencing: a multimodality test for management of cancer. Curr. Hematol. Malig. Rep. 14, 358–367 (2019).
pubmed: 31346903
doi: 10.1007/s11899-019-00532-w
Glenn, T. C. Field guide to next-generation DNA sequencers. Mol. Ecol. Resour. 11, 759–769 (2011).
pubmed: 21592312
doi: 10.1111/j.1755-0998.2011.03024.x
Kinde, I., Wu, J., Papadopoulos, N., Kinzler, K. W. & Vogelstein, B. Detection and quantification of rare mutations with massively parallel sequencing. Proc. Natl Acad. Sci. USA 108, 9530–9535 (2011).
pubmed: 21586637
pmcid: 3111315
doi: 10.1073/pnas.1105422108
Schmitt, M. W., Kennedy, S. R., Salk, J. J., Fox, E. J., Hiatt, J. B. & Loeb, L. A. Detection of ultra-rare mutations by next-generation sequencing. Proc. Natl Acad. Sci. USA 109, 14508–14513 (2012).
pubmed: 22853953
pmcid: 3437896
doi: 10.1073/pnas.1208715109
Phallen, J., Sausen, M., Adleff, V., Leal, A., Hruban, C., White, J. et al. Direct detection of early-stage cancers using circulating tumor DNA. Sci. Transl. Med. 9, eaan2415 (2017).
pubmed: 28814544
pmcid: 6714979
doi: 10.1126/scitranslmed.aan2415
Newman, A. M., Lovejoy, A. F., Klass, D. M., Kurtz, D. M., Chabon, J. J., Scherer, F. et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat. Biotechnol. 34, 547–555 (2016).
pubmed: 27018799
pmcid: 4907374
doi: 10.1038/nbt.3520
Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 70, 7–30 (2020).
pubmed: 31912902
doi: 10.3322/caac.21590
Siu, A. L. & Force, U. S. P. S. T. Screening for breast cancer: U.S. preventive services task force recommendation statement. Ann. Intern. Med. 164, 279–296 (2016).
pubmed: 26757170
doi: 10.7326/M15-2886
Agassi, R., Czeiger, D., Shaked, G., Avriel, A., Sheynin, J., Lavrenkov, K. et al. Measurement of circulating cell-free DNA levels by a simple fluorescent test in patients with breast cancer. Am. J. Clin. Pathol. 143, 18–24 (2015).
pubmed: 25511138
doi: 10.1309/AJCPI5YHG0OGFAHM
Gong, B., Xue, J., Yu, J., Li, H., Hu, H., Yen, H. et al. Cell-free DNA in blood is a potential diagnostic biomarker of breast cancer. Oncol. Lett. 3, 897–900 (2012).
pubmed: 22741014
pmcid: 3362401
Yu, D., Tong, Y., Guo, X., Feng, L., Jiang, Z., Ying, S. et al. Diagnostic value of concentration of circulating cell-free DNA in breast cancer: a meta-analysis. Front. Oncol. 9, 95 (2019).
pubmed: 30881916
pmcid: 6405437
doi: 10.3389/fonc.2019.00095
Peled, M., Agassi, R., Czeiger, D., Ariad, S., Riff, R., Rosenthal, M. et al. Cell-free DNA concentration in patients with clinical or mammographic suspicion of breast cancer. Sci. Rep. 10, 14601 (2020).
pubmed: 32884019
pmcid: 7471679
doi: 10.1038/s41598-020-71357-4
Beaver, J. A., Jelovac, D., Balukrishna, S., Cochran, R., Croessmann, S., Zabransky, D. J. et al. Detection of cancer DNA in plasma of patients with early-stage breast cancer. Clin. Cancer Res. 20, 2643–2650 (2014).
pubmed: 24504125
pmcid: 4024333
doi: 10.1158/1078-0432.CCR-13-2933
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N. et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. 6, 224ra224 (2014).
doi: 10.1126/scitranslmed.3007094
Chan, K. C. A., Woo, J. K. S., King, A., Zee, B. C. Y., Lam, W. K. J., Chan, S. L. et al. Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer. N. Engl. J. Med. 377, 513–522 (2017).
pubmed: 28792880
doi: 10.1056/NEJMoa1701717
Cohen, J. D., Li, L., Wang, Y., Thoburn, C., Afsari, B., Danilova, L. et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 359, 926–930 (2018).
pubmed: 29348365
pmcid: 6080308
doi: 10.1126/science.aar3247
Lennon, A. M., Buchanan, A. H., Kinde, I., Warren, A., Honushefsky, A., Cohain, A. T. et al. Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. Science 369, eabb9601 (2020).
pubmed: 32345712
pmcid: 7509949
doi: 10.1126/science.abb9601
de Almeida, B. P., Apolonio, J. D., Binnie, A. & Castelo-Branco, P. Roadmap of DNA methylation in breast cancer identifies novel prognostic biomarkers. BMC Cancer 19, 219 (2019).
pubmed: 30866861
pmcid: 6416975
doi: 10.1186/s12885-019-5403-0
Xu, Z., Sandler, D. P. & Taylor, J. A. Blood DNA methylation and breast cancer: a prospective case-cohort analysis in the sister study. J. Natl Cancer Inst. 112, 87–94 (2020).
pubmed: 30989176
doi: 10.1093/jnci/djz065
Shen, S. Y., Singhania, R., Fehringer, G., Chakravarthy, A., Roehrl, M. H. A., Chadwick, D. et al. Sensitive tumour detection and classification using plasma cell-free DNA methylomes. Nature 563, 579–583 (2018).
pubmed: 30429608
doi: 10.1038/s41586-018-0703-0
Liu, M. C., Jamshidi, A., Venn, O., Fields, A. P., Maher, M. C., Cann, G. et al. Genome-wide cell-free DNA (cfDNA) methylation signatures and effect on tissue of origin (TOO) performance. J. Clin. Oncol. 37, 3049–3049 (2019).
doi: 10.1200/JCO.2019.37.15_suppl.3049
Rothe, F., Silva, M. J., Venet, D., Campbell, C., Bradburry, I., Rouas, G. et al. Circulating tumor DNA in HER2-amplified breast cancer: a translational research substudy of the NeoALTTO Phase III Trial. Clin. Cancer Res. 25, 3581–3588 (2019).
pubmed: 30862692
doi: 10.1158/1078-0432.CCR-18-2521
Oshiro, C., Kagara, N., Naoi, Y., Shimoda, M., Shimomura, A., Maruyama, N. et al. PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients. Breast Cancer Res. Treat. 150, 299–307 (2015).
pubmed: 25736040
doi: 10.1007/s10549-015-3322-6
Goh, J. Y., Feng, M., Wang, W., Oguz, G., Yatim, S., Lee, P. L. et al. Chromosome 1q21.3 amplification is a trackable biomarker and actionable target for breast cancer recurrence. Nat. Med. 23, 1319–1330 (2017).
pubmed: 28967919
doi: 10.1038/nm.4405
Widschwendter, M., Evans, I., Jones, A., Ghazali, S., Reisel, D., Ryan, A. et al. Methylation patterns in serum DNA for early identification of disseminated breast cancer. Genome Med. 9, 115 (2017).
pubmed: 29268762
pmcid: 5740791
doi: 10.1186/s13073-017-0499-9
Cavallone, L., Aguilar-Mahecha, A., Lafleur, J., Brousse, S., Aldamry, M., Roseshter, T. et al. Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer. Sci. Rep. 10, 14704 (2020).
pubmed: 32895401
pmcid: 7477566
doi: 10.1038/s41598-020-71236-y
Riva, F., Bidard, F. C., Houy, A., Saliou, A., Madic, J., Rampanou, A. et al. Patient-specific circulating tumor DNA detection during neoadjuvant chemotherapy in triple-negative breast cancer. Clin. Chem. 63, 691–699 (2017).
pubmed: 28073896
doi: 10.1373/clinchem.2016.262337
McDonald, B. R., Contente-Cuomo, T., Sammut, S. J., Odenheimer-Bergman, A., Ernst, B., Perdigones, N. et al. Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer. Sci. Transl. Med. 11, eaax7392 (2019).
pubmed: 31391323
pmcid: 7236617
doi: 10.1126/scitranslmed.aax7392
Cheng, L., Swartz, M. D., Zhao, H., Kapadia, A. S., Lai, D., Rowan, P. J. et al. Hazard of recurrence among women after primary breast cancer treatment-a 10-year follow-up using data from SEER-Medicare. Cancer Epidemiol. Biomarkers Prev. 21, 800–809 (2012).
pubmed: 22426147
doi: 10.1158/1055-9965.EPI-11-1089
Garcia-Murillas, I., Schiavon, G., Weigelt, B., Ng, C., Hrebien, S., Cutts, R. J. et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci. Transl. Med. 7, 302ra133 (2015).
pubmed: 26311728
doi: 10.1126/scitranslmed.aab0021
Olsson, E., Winter, C., George, A., Chen, Y., Howlin, J., Tang, M. H. et al. Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. EMBO Mol. Med. 7, 1034–1047 (2015).
pubmed: 25987569
pmcid: 4551342
doi: 10.15252/emmm.201404913
Parsons, H. A., Rhoades, J., Reed, S. C., Gydush, G., Ram, P., Exman, P. et al. Sensitive detection of minimal residual disease in patients treated for early-stage breast cancer. Clin. Cancer Res. 26, 2556–2564 (2020).
pubmed: 32170028
pmcid: 7654718
doi: 10.1158/1078-0432.CCR-19-3005
Coombes, R. C., Page, K., Salari, R., Hastings, R. K., Armstrong, A., Ahmed, S. et al. Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence. Clin. Cancer Res. 25, 4255–4263 (2019).
pubmed: 30992300
doi: 10.1158/1078-0432.CCR-18-3663
Dawson, S. J., Tsui, D. W., Murtaza, M., Biggs, H., Rueda, O. M., Chin, S. F. et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N. Engl. J. Med. 368, 1199–1209 (2013).
pubmed: 23484797
doi: 10.1056/NEJMoa1213261
Kodahl, A. R., Ehmsen, S., Pallisgaard, N., Jylling, A. M. B., Jensen, J. D., Laenkholm, A. V. et al. Correlation between circulating cell-free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA-mutated metastatic breast cancer. Mol. Oncol. 12, 925–935 (2018).
pubmed: 29689598
pmcid: 5983134
doi: 10.1002/1878-0261.12305
Liang, D. H., Ensor, J. E., Liu, Z. B., Patel, A., Patel, T. A., Chang, J. C. et al. Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients. Breast Cancer Res. Treat. 155, 139–149 (2016).
pubmed: 26667234
doi: 10.1007/s10549-015-3635-5
O’Leary, B., Hrebien, S., Morden, J. P., Beaney, M., Fribbens, C., Huang, X. et al. Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer. Nat. Commun. 9, 896 (2018).
pubmed: 29497091
pmcid: 5832789
doi: 10.1038/s41467-018-03215-x
Karthikeyan, S., Waters, I. G., Dennison, L., Chu, D., Donaldson, J., Shin, D. H. et al. Hierarchical tumor heterogeneity mediated by cell contact between distinct genetic subclones. J. Clin. Invest. 131, e143557 (2021).
pmcid: 7954606
doi: 10.1172/JCI143557
Frenel, J. S., Carreira, S., Goodall, J., Roda, D., Perez-Lopez, R., Tunariu, N. et al. Serial next-generation sequencing of circulating cell-free DNA evaluating tumor clone response to molecularly targeted drug administration. Clin. Cancer Res. 21, 4586–4596 (2015).
pubmed: 26085511
pmcid: 4580992
doi: 10.1158/1078-0432.CCR-15-0584
Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N. et al. Drug resistance in cancer: an overview. Cancers 6, 1769–1792 (2014).
pubmed: 25198391
pmcid: 4190567
doi: 10.3390/cancers6031769
Longley, D. B. & Johnston, P. G. Molecular mechanisms of drug resistance. J. Pathol. 205, 275–292 (2005).
pubmed: 15641020
doi: 10.1002/path.1706
Turner, N. C., Kingston, B., Kilburn, L. S., Kernaghan, S., Wardley, A. M., Macpherson, I. R. et al. Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. Lancet Oncol. 21, 1296–1308 (2020).
pubmed: 32919527
pmcid: 7599319
doi: 10.1016/S1470-2045(20)30444-7
Toy, W., Shen, Y., Won, H., Green, B., Sakr, R. A., Will, M. et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat. Genet. 45, 1439–1445 (2013).
pubmed: 24185512
pmcid: 3903423
doi: 10.1038/ng.2822
Robinson, D. R., Wu, Y. M., Vats, P., Su, F., Lonigro, R. J., Cao, X. et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat. Genet. 45, 1446–1451 (2013).
pubmed: 24185510
pmcid: 4009946
doi: 10.1038/ng.2823
Schiavon, G., Hrebien, S., Garcia-Murillas, I., Cutts, R. J., Pearson, A., Tarazona, N. et al. Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Sci. Transl. Med. 7, 313ra182 (2015).
pubmed: 26560360
pmcid: 4998737
doi: 10.1126/scitranslmed.aac7551
Chandarlapaty, S., Chen, D., He, W., Sung, P., Samoila, A., You, D. et al. Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 Clinical Trial. JAMA Oncol. 2, 1310–1315 (2016).
pubmed: 27532364
pmcid: 5063698
doi: 10.1001/jamaoncol.2016.1279
Spoerke, J. M., Gendreau, S., Walter, K., Qiu, J., Wilson, T. R., Savage, H. et al. Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant. Nat. Commun. 7, 11579 (2016).
pubmed: 27174596
pmcid: 4869259
doi: 10.1038/ncomms11579
Fribbens, C., O’Leary, B., Kilburn, L., Hrebien, S., Garcia-Murillas, I., Beaney, M. et al. Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer. J. Clin. Oncol. 34, 2961–2968 (2016).
pubmed: 27269946
doi: 10.1200/JCO.2016.67.3061
Wang, P., Bahreini, A., Gyanchandani, R., Lucas, P. C., Hartmaier, R. J., Watters, R. J. et al. Sensitive detection of mono- and polyclonal ESR1 mutations in primary tumors, metastatic lesions, and cell-free DNA of breast cancer patients. Clin. Cancer Res. 22, 1130–1137 (2016).
pubmed: 26500237
doi: 10.1158/1078-0432.CCR-15-1534
Li, J., Huo, X., Zhao, F., Ren, D., Ahmad, R., Yuan, X. et al. Association of cyclin-dependent kinases 4 and 6 inhibitors with survival in patients with hormone receptor-positive metastatic breast cancer: a systematic review and meta-analysis. JAMA Netw. Open 3, e2020312 (2020).
pubmed: 33048129
pmcid: 8094425
doi: 10.1001/jamanetworkopen.2020.20312
Sledge, G. W., Jr., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X. et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2019.4782 (2019).
Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S. A., Masuda, N. et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N. Engl. J. Med. 379, 1926–1936 (2018).
pubmed: 30345905
doi: 10.1056/NEJMoa1810527
O’Leary, B., Cutts, R. J., Liu, Y., Hrebien, S., Huang, X., Fenwick, K. et al. The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial. Cancer Discov. 8, 1390–1403 (2018).
pubmed: 30206110
pmcid: 6368247
doi: 10.1158/2159-8290.CD-18-0264
Bidard, F. C., Callens, C., Dalenc, F., Pistilli, B., Rouge, T. D. L. M., Clatot, F. et al. Prognostic impact of ESR1 mutations in ER+ HER2- MBC patients prior treated with first line AI and palbociclib: an exploratory analysis of the PADA-1 trial. J. Clin. Oncol. 38, 1010 (2020).
doi: 10.1200/JCO.2020.38.15_suppl.1010
Turner, N. C., Swift, C., Kilburn, L., Fribbens, C., Beaney, M., Garcia-Murillas, I. et al. ESR1 mutations and overall survival on fulvestrant versus exemestane in advanced hormone receptor-positive breast cancer: a combined analysis of the Phase III SoFEA and EFECT Trials. Clin. Cancer Res. 26, 5172–5177 (2020).
pubmed: 32546646
doi: 10.1158/1078-0432.CCR-20-0224
Bardia, A., Aftimos, P., Bihani, T., Anderson-Villaluz, A. T., Jung, J., Conlan, M. G. et al. EMERALD: phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer. Fut. Oncol. 15, 3209–3218 (2019).
doi: 10.2217/fon-2019-0370
Kaklamani, V., Bardia, A., Wilks, S., Weise, A., Richards, D., Harb, W. et al. Final analysis of phase 1 study of elacestrant (RAD1901), a novel selective estrogen receptor degrader (SERD), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer. Cancer Res. 80, PD7–PD07 (2020).
doi: 10.1158/1538-7445.SABCS19-PD7-07
Higgins, M. J., Jelovac, D., Barnathan, E., Blair, B., Slater, S., Powers, P. et al. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin. Cancer Res. 18, 3462–3469 (2012).
pubmed: 22421194
pmcid: 3533370
doi: 10.1158/1078-0432.CCR-11-2696
Andre, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S. et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N. Engl. J. Med. 380, 1929–1940 (2019).
pubmed: 31091374
doi: 10.1056/NEJMoa1813904
Juric, D., Castel, P., Griffith, M., Griffith, O. L., Won, H. H., Ellis, H. et al. Convergent loss of PTEN leads to clinical resistance to a PI(3)Kalpha inhibitor. Nature 518, 240–244 (2015).
pubmed: 25409150
doi: 10.1038/nature13948
Razavi, P. Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors. Nat. Cancer 1, 382–393 (2020).
pubmed: 32864625
pmcid: 7450824
doi: 10.1038/s43018-020-0047-1